Skip to main content
SpringerLink
Log in

Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

To validate our initial pilot study and confirm sustained safety and tumor response of extended-shelf-life 90Y glass microspheres. We hypothesized that for the same planned tissue dose, the increase in number of glass microspheres (decayed to the second week of their allowable shelf-life) administered for the same absorbed dose would result in better tumor distribution of the microspheres without causing additional adverse events.

Methods

Between June 2007 and January 2010, 134 patients underwent radioembolization with extended-shelf-life 90Y glass microspheres; data from 84 new patients were combined with data from our 50-patient pilot study cohort. Baseline and follow-up imaging and laboratory data were obtained 1 and 3 months after therapy and every 3 months thereafter. Clinical and biochemical toxicities were prospectively captured and categorized according to the Common Terminology Criteria. Response in the index lesion was assessed using WHO and EASL guidelines.

Results

The mean delivered radiation dose was 123 Gy to the target liver tissue. The mean increase in number of microspheres with this approach compared to standard 90Y glass microsphere dosimetry was 103 %, corresponding to an increase from 3.84 to 7.78 million microspheres. Clinical toxicities included fatigue (89 patients, 66 %), abdominal pain (49 patients, 36.6 %), and nausea/vomiting (25 patients, 18.7 %). Grade 3/4 bilirubin toxicity was seen in three patients (2 %). Two (1 %) of the initial 50-patient cohort showed gastroduodenal ulcers; gastroduodenal ulcers were not seen in any of the subsequent 84 patients. According to WHO and EASL guidelines, response rates were 48 % and 57 %, respectively, and 21 % demonstrated a complete EASL response.

Conclusion

This study showed sustained safety and efficacy of extended-shelf-life 90Y glass microspheres in a larger, 134-patient cohort. The increase in number of microspheres administered theoretically resulted in better tumor distribution of the microspheres without an increase in adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22:265–78.

    Article  PubMed  Google Scholar 

  2. Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141:526–35; 535.e521-522.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A. Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers. Am J Clin Oncol. 2012;35:167–77.

    Article  PubMed  Google Scholar 

  4. Nace GW, Steel JL, Amesur N, Zajko A, Nastasi BE, Joyce J, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol. 2011;2011:571261.

    PubMed Central  PubMed  Google Scholar 

  5. Therasphere yttrium-90 microspheres [package insert]. Kanata, Canada: MDS Nordion; 2004.

  6. SIR-Spheres yttrium-90 microspheres [package insert]. Lane Cove, Australia: Sirtex Medical; 2004.

  7. Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, et al. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol. 2007;18:1588–91.

    Article  PubMed  Google Scholar 

  8. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13–23.

    Article  PubMed  Google Scholar 

  9. Lewandowski RJ, Riaz A, Ryu RK, Mulcahy MF, Sato KT, Kulik LM, et al. Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study. J Vasc Interv Radiol. 2009;20:1557–63.

    Article  PubMed  Google Scholar 

  10. Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol. 2000;45:1023–33.

    Article  CAS  PubMed  Google Scholar 

  11. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627–39.

    Article  PubMed  Google Scholar 

  12. Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek Jr AA, Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571–92.

    Article  PubMed  Google Scholar 

  13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  CAS  PubMed  Google Scholar 

  14. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.

    Article  CAS  PubMed  Google Scholar 

  15. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology. 2009;49:1185–93.

    Article  PubMed  Google Scholar 

  16. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.

    Article  PubMed  Google Scholar 

  17. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol. 2006;17:1571–93.

    Article  PubMed  Google Scholar 

  18. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29:522–9.

    Article  PubMed  Google Scholar 

  19. Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15:335–45.

    Article  PubMed  Google Scholar 

  20. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71–81.

    Article  PubMed  Google Scholar 

  21. Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16:937–45.

    Article  PubMed  Google Scholar 

  22. Koukourakis MI. Tumour angiogenesis and response to radiotherapy. Anticancer Res. 2001;21:4285–300.

    CAS  PubMed  Google Scholar 

  23. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;13:S0168–8278.

    Google Scholar 

  24. Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, et al. Boosted selective internal radiation therapy with (90)Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057–68.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, et al. Volumetric changes after (90)Y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 2013;20:2518–25.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

This research was not sponsored by an organization. Riad Salem is a paid consultant to Nordion. Robert J. Lewandowski is an advisor to Nordion. The remaining authors declare they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Radiology, Northwestern University, 676 N St Clair St, Suite 800, Chicago, IL, USA

    Robert J. Lewandowski, Jeet Minocha, Khairuddin Memon, Ahsun Riaz, Vanessa L. Gates, Robert K. Ryu, Kent T. Sato, Reed Omary & Riad Salem

Authors
  1. Robert J. Lewandowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeet Minocha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Khairuddin Memon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahsun Riaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vanessa L. Gates
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert K. Ryu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kent T. Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Reed Omary
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Riad Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Lewandowski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lewandowski, R.J., Minocha, J., Memon, K. et al. Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort. Eur J Nucl Med Mol Imaging 41, 486–493 (2014). https://doi.org/10.1007/s00259-013-2575-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-013-2575-8

Keywords

Search

Navigation